Replies to post #145270 on Biotech Values

[jq1234]

But I concede they might well have presented the subgroup OS numbers if they were favorable

They said no OS benefit trend for FR++ sub-group either. Someone can correct me if I am wrong here.

The control group did do surprisingly well for a purportedly platinum-resistant population. But it's under 50 patients, so a handful who did well can skew the numbers quite a bit.

This is the only point left. This is too subjective to rely upon.

[turtlepower]

ECYT - Any thoughts on whether ECYT's approach of using smdc's would work for inflammatory diseases? The inflammation IND is about a year away but the ability to use the smdc approach in non-oncology indications is interesting.